Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.

I call it my AI Retirement Playbook. I recommend you check it out now.

Eli Shani Biography and Net Worth

EVP of Teva Pharmaceutical Industries

Eli Shani was appointed Executive Vice President, Global Marketing and Portfolio in 2021.

The Global Marketing & Portfolio function is responsible for maximizing the value of Teva’s generic, biosimilar and specialty portfolio across the company’s commercial regions, including brokering business development opportunities. The group oversees the interconnections between commercial markets, R&D, operations and external partners through all product lifecycle stages.

Eli served as Senior Vice President of Business Development at Teva since 2018 and assumed additional responsibility for Alliance Management early in 2021 prior to being appointed leader of Teva’s Global Marketing & Portfolio organization and joining the company’s Executive Management team later in 2021.

Prior to that, Eli held several senior leadership roles at Teva including Senior Vice President, Strategic Initiatives, International Markets; Chief Operating Officer of a joint venture formed by Teva and Procter & Gamble; and Vice President in Teva's Corporate Business Development group.

Before joining Teva, Eli was Chief Financial Officer and head of business development at a medical diagnostics company, and prior to that, he held leadership roles in finance and banking with CIBC World Markets and Credit Suisse.

He holds a joint degree in law and accounting from the University of Tel Aviv and an MBA from the University of Chicago.

How do I contact Eli Shani?: The corporate mailing address for Shani and other Teva Pharmaceutical Industries executives is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. Teva Pharmaceutical Industries can also be reached via phone at (723) 914-8213 and via email at [email protected]. Learn More on Eli Shani's contact information.
Has Eli Shani been buying or selling shares of Teva Pharmaceutical Industries?: Eli Shani has not been actively trading shares of Teva Pharmaceutical Industries within the last three months. Most recently, Eli Shani sold 5,311 shares of the business's stock in a transaction on Monday, February 28th. The shares were sold at an average price of $8.14, for a transaction totalling $43,231.54. Learn More on Eli Shani's trading history.
Who are Teva Pharmaceutical Industries' active insiders?: Teva Pharmaceutical Industries' insider roster includes Vikki Conway (Acting Head of Global Human Resources), Rosemary Crane (Director), Richard Daniell (VP), Sven Dethlefs (EVP), Eric Drape (VP), Christine Fox (EVP, U.S. Commercial), Richard Francis (President, CEO & Director), Hafrun Fridriksdottir (VP), Eric Hughes (insider), Eliyahu Kalif (CFO), Roberto Mignone (Director), Mark Sabag (Insider), Eli Shani (EVP), David Stark (VP), and Amir Weiss (CAO). Learn More on Teva Pharmaceutical Industries' active insiders.
Are insiders buying or selling shares of Teva Pharmaceutical Industries?: During the last twelve months, insiders at the sold shares 11 times. They sold a total of 984,382 shares worth more than $15,236,840.56. The most recent insider tranaction occured on November, 20th when EVP Christine Fox sold 19,388 shares worth more than $327,075.56. Insiders at Teva Pharmaceutical Industries own 0.6% of the company. Learn More about insider trades at Teva Pharmaceutical Industries.
Information on this page was last updated on 11/20/2024.

Eli Shani Insider Trading History at Teva Pharmaceutical Industries

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/28/2022	Sell	5,311	$8.14	$43,231.54

Eli Shani Buying and Selling Activity at Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Company Overview

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Today's Range

Now: $22.42

$22.19

$22.50

50 Day Range

MA: $17.97

$16.44

$22.42

2 Week Range

Now: $22.42

$10.34

$22.50

Volume

3,025,977 shs

Average Volume

9,430,263 shs

Market Capitalization

$25.40 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.79

Most People Are Dead Wrong.

From Brownstone Research | Ad